RWPA
RXRX icon

Richard W. Paul & Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

Richard W. Paul & Associates’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-424
Closed -$2.87K – 478
2024
Q4 		$2.87K Hold
424
– – ﹤0.01% 394
2024
Q3 		$2.79K Hold
424
– – ﹤0.01% 392
2024
Q2 		$3.18K Hold
424
– – ﹤0.01% 379
2024
Q1 		$4.23K Buy
+424
New +$4.72K ﹤0.01% 368

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Richard W. Paul & Associates's RXRX Position: Q1 2025 in Review

Richard W. Paul & Associates sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 424 shares — an estimated $2.87K sold.

Richard W. Paul & Associates first reported a position in RXRX in Q1 2024 and held it in 4 quarters. The position peaked at $4.23K in Q1 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Richard W. Paul & Associates reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Richard W. Paul & Associates sold 424 Recursion Pharmaceuticals shares in Q1 2025, an estimated $2.87K.
  • Richard W. Paul & Associates first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Richard W. Paul & Associates's Recursion Pharmaceuticals position peaked at $4.23K in Q1 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Richard W. Paul & Associates's 13F filing for Q1 2025, filed 12 May 2025.